Roger M. Perlmutter, MD, PhD
In the KEYNOTE-006 study, which compared 2 pembrolizumab regimens with ipilimumab, the PD-L1 inhibitor reduced the risk of disease progression by >40% and the risk of death by >30%.
"As recently as five years ago, there were few treatment options for patients suffering from advanced melanoma," Roger M. Perlmutter, MD, PhD, president, Merck Research Laboratories, the developer of the PD-1 inhibitor, said in a statement. “Today’s news is another exciting milestone for Keytruda and for patients with this disease." Click here to read the full article at OncLive.com